ALTACE
Drug
PFIZER INC.
Total Payments
$1.3M
Transactions
11
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.3M | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 11 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY OF RAMIPRIL TO PREVENT ICU ADMISSION MECHANICAL VENTILATION OR DEATH IN PERSONS WITH COVID19 | PFIZER INC. | $1.3M | 0 |
Top Doctors Receiving Payments for ALTACE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | La Jolla, CA | $1.3M | 11 |
Ad
Manufacturing Companies
- PFIZER INC. $1.3M
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 0
- Transactions 11
About ALTACE
ALTACE is a drug associated with $1.3M in payments to 0 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2020 to 2020. In 2020, $1.3M was paid across 11 transactions to 0 doctors.
The most common payment nature for ALTACE is "Unspecified" ($1.3M, 100.0% of total).
ALTACE is associated with 1 research study, including "A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY OF RAMIPRIL TO PREVENT ICU ADMISSION MECHANICAL VENTILATION OR DEATH IN PERSONS WITH COVID19" ($1.3M).